無料セミナー : 2020年3月4日『Future of Immuno-Oncology 免疫腫瘍学の未来』 DelveInsight Business Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血液癌の世界市場の分析・予測 (~2028年):免疫療法・化学療法・標的療法

Global Blood Cancer Market Forecast to 2028: Immunotherapy, Chemotherapy, Targeted Therapy

発行 Visiongain Ltd 商品コード 862036
出版日 ページ情報 英文 92 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.23円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
血液癌の世界市場の分析・予測 (~2028年):免疫療法・化学療法・標的療法 Global Blood Cancer Market Forecast to 2028: Immunotherapy, Chemotherapy, Targeted Therapy
出版日: 2019年04月11日 ページ情報: 英文 92 Pages
概要

世界の血液癌の市場は2018年の240億ドルから、予測期間前半は6.4%のCAGR (年間複合成長率) で成長すると予測されています。

当レポートでは、世界の血液癌の市場を調査し、血液癌の臨床的概要、治療タイプ・地域/主要国別の動向と市場規模の推移と予測、R&Dパイプラインの動向、主要動向・市場への各種影響因子の分析、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 世界の血液癌市場:罹患数

  • 概要
  • 兆候・症状
  • 原因
  • 治療・治療オプション
  • 白血病
    • 成人急性リンパ性白血病 (ALL)
    • 急性骨髄性白血病 (AML)
    • 慢性リンパ性白血病 (CLL)
    • 慢性骨髄性白血病 (CML)
    • 慢性骨髄単球性白血病
    • 小児白血病
    • 生存率
  • リンパ腫
    • 非ホジキンリンパ腫
    • ホジキン病
    • 生存率
  • 骨髄腫
    • 生存率

第3章 市場分析・予測:治療タイプ別

  • イントロダクション
  • 化学療法
  • 免疫療法

第4章 市場分析・予測:地域別

  • イントロダクション
  • 米国
  • EU5カ国
  • BRIC諸国
  • 日本

第5章 主要企業

  • イントロダクション
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc.

第6章 血液癌:R&Dパイプライン

  • 白血病
  • リンパ腫
  • 多発性骨髄腫
  • その他

第7章 定性分析

  • ポーターのファイブフォース分析
  • 市場力学
    • 動向
    • 成長推進因子
    • 課題

第8章 総論・提言

付録

図表

List of Tables

  • Table 2.1: Incident Cases of Leukaemia by Country: 2018-2028
  • Table 2.2: Incident cases of Non-Hodgkin Lymphoma (NHL) by Country: 2018-2028
  • Table 2.3: Incident Cases of Hodgkin Lymphoma (HL) by Country: 2018-2028
  • Table 2.4: Incident cases of Multiple Myeloma by Country: 2018-2028
  • Table 3.1: Global Blood Cancer Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 3.2: Global Chemotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CARG (%), 2018-2028
  • Table 3.3: Global Targeted Therapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
  • Table 3.4: Global Immunotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.1: United States Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.2: Incident Cases of Different Types of Cancers in the US: 2018-2028
  • Table 4.3: United States Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.4: EU5 Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.5: Incident Cases of Different Types of Cancers in the EU5
  • Table 4.6: EU5 Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.7: BRIC Blood Cancer Market Forecast 2018-2028 by Country: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.8: Incident Cases of Different Types of Cancers in BRIC Countries: 2018-2028
  • Table 4.9: BRIC Countries Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), 2018-2028
  • Table 4.10: Japan Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
  • Table 4.11: Incident Cases of Different Types of Cancers in Japan: 2018-2028
  • Table 4.12: Japan Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), 2018-2028
  • Table 5.1: Amgen Inc.: Key Facts
  • Table 5.2: Amgen Inc.: Financial Information 2016-2017
  • Table 5.3: AstraZeneca PLC: Key Facts
  • Table 5.4: AstraZeneca PLC: Financial Information 2016-2017
  • Table 5.5: Bayer AG: Key Facts
  • Table 5.6: Bayer AG: Recent Financials 2016-2017
  • Table 5.7: Bristol-Myers Squibb Company - Key Facts
  • Table 5.8: Bristol-Myers Squibb: Recent Financials 2016-2017
  • Table 5.9: Celgene Corporation: Key Facts
  • Table 5.10: Celgene: Recent Financials 2016-2017
  • Table 5.11: Roche: Key Facts
  • Table 5.12: Roche: Recent Financials 2016-2017
  • Table 5.13: Johnson & Johnson: Key Facts
  • Table 5.14: Johnson & Johnson: Recent Financials 2016-2017
  • Table 5.15: Novartis AG: Key Facts
  • Table 5.16: Novartis: Recent Financials 2016-2017
  • Table 5.17: Pfizer Inc.: Key Facts
  • Table 5.18: Pfizer Inc.: Recent Financials 2016-2017
  • Table 6.1: Major Drugs Udder Development

List of Figures

  • Figure 2.1: Types of Blood Cancer
  • Figure 2.2: Different Types of Leukaemia
  • Figure 2.3: Trend of Leukaemia Cases by Country: 2018-2028
  • Figure 2.4: Trend of Non-Hodgkin Lymphoma (NHL) by Country: 2018-2028
  • Figure 2.5: Trend of Hodgkin Lymphoma (NHL) by Country: 2018-2028
  • Figure 2.6: Trend of Multiple Myeloma by Country: 2018-2028
  • Figure 3.1: Market Size of Cancer Therapy by Type ($bn): 2018-2028
  • Figure 3.2: Market share (%) of Cancer Therapy by Type: 2018 and 2028
  • Figure 3.3: Global Chemotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 3.4: Global Targeted Therapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 3.5: Global Immunotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 4.1: Blood Cancer Market by Region: % Share, 2018
  • Figure 4.2: Blood Cancer Market by Region: % Share, 2028
  • Figure 4.3: United States Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 4.4: Distribution of Different Types of Blood Cancer in the US: 2018-2028
  • Figure 4.5: EU5 Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 4.6: EU5 Blood Cancer Market by Country: % Share, 2018 and 2028
  • Figure 4.7: BRIC Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 4.8: Japan Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
  • Figure 4.9: Distribution of Different Types of Blood Cancer in Japan: 2018-2028
  • Figure 8.1: Global Blood Cancer Market by Region: Revenue ($bn), 2018
  • Figure 8.2: Global Blood Cancer Market by Region: Revenue ($bn), 2018

COMPANIES LISTED:

  • Acceleron Pharma, Inc.
  • Acerta Pharma
  • Advantagene, Inc
  • Agios Pharmaceuticals, Inc.
  • Alcon
  • Amgen
  • Array BioPharma
  • AstraZeneca
  • Bayer AG
  • Bayer HealthCare Pharmaceuticals Inc
  • BeiGene, Ltd
  • Bicycle Therapeutics
  • BioSight
  • bluebird bio, Inc.
  • Bristol-Myers Squibb (BMS)
  • Celgene
  • Evotec AG
  • Fate Therapeutics
  • Food and Drug Administration (FDA)
  • FORMA Therapeutics Holdings, LLC
  • Forty Seven, Inc.
  • Genentech
  • GlaxoSmithKline
  • Hoffmann-La Roche
  • Hospira, Inc.
  • Illumina, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Jounce Therapeutics, Inc.
  • Juno Therapeutics, Inc.
  • Lycera Corp.
  • MacroGenics
  • NantBioScience, Inc.
  • National Health Service (NHS)
  • Nektar Therapeutics
  • Novartis
  • Nurix Inc.
  • OncoMed Pharmaceuticals, Inc.
  • Pfizer
  • Prothena Corporation plc
  • Roche
  • Servizio Sanitario Nazionale (SSN)
  • Skyhawk Therapeutics, Inc.
  • Surface Oncology
  • Sutro Biopharma, Inc.
  • The University of Texas MD Anderson Cancer Center
  • U.S. Department of Energy
  • UCB
  • Vividion Therapeutics, Inc.
  • Zoetis Inc.
  • Zymeworks Inc.
目次
Product Code: PHA0412

The global blood cancer market reached $24bn in 2018 and is estimated to grow at a CAGR of 6.4% in the first half of the forecast period. Chemotherapy held 44% of the market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new report you will receive 61 charts - all unavailable elsewhere.

This report provides clear detailed insight into the global blood cancer market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Revenue and growth forecasts to 2028 for the blood cancer market

Revenue and growth forecast to 2028 for the blood cancer market by type of therapy:

  • Chemotherapy
  • Targeted therapy
  • Immunotherapy

Revenue and growth forecast to 2028 for the blood cancer market by regional and national market:

  • The US
  • Japan
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Brazil
  • Russia
  • India
  • China

For each national market, the revenue forecast is also broken down by submarket.

For each national market, this report provides incident cases projection from 2018 to 2028 for:

  • Leukaemia
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Multiple Myeloma

Discussion and profiles of the leading players in the blood cancer market:

  • Amgen
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb (BMS)
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche

Discussion on drugs that are currently in the R&D pipeline for Leukaemia, Lymphoma and Multiple Myeloma.

Analysis of what stimulates and restrains the global blood cancer market: Porter's Five Forces Analysis, Trends, Drivers and Challenges.

Key Questions Answered by this Report:

  • How is the Blood Cancer market evolving?
  • What are the drivers and restraints for the growth of the Blood Cancer market?
  • How will each Blood Cancer submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2028?
  • What will be the main driver for the overall market to 2028?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Will leading national Blood Cancer markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?
  • Who are the leading players and what are their prospects over the forecast period?

Visiongain's study is intended for anyone requiring commercial analyses for the global blood cancer market. You find data, trends and predictions.

Buy our report today Global Blood Cancer Market Forecast to 2028: Immunotherapy, Chemotherapy, Targeted Therapy.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Blood Cancer Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Why You Should Read This Report
  • 1.5. How This Report Delivers
  • 1.6. Key Questions Answered by This Analytical Report
  • 1.7. Who is This Report For?
  • 1.8. Methodology
    • 1.8.1. Primary Research
    • 1.8.2. Secondary Research
    • 1.8.3. Market Evaluation & Forecasting Methodology
  • 1.9. Frequently Asked Questions (FAQ)
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. The Global Blood Cancer Market by Therapy Area: Incident Cases by Country 2018-2018

  • 2.1. Overview of Blood Cancer
  • 2.2. Signs and Symptoms
  • 2.3. Causes of Blood Cancer
  • 2.4. Blood Cancer Treatment & Therapy Options
  • 2.5. Leukaemia
    • 2.5.1. Acute Lymphocytic Leukaemia (ALL) in Adults
    • 2.5.2. Acute Myeloid Leukaemia (AML)
    • 2.5.3. Chronic Lymphocytic Leukaemia (CLL)
    • 2.5.4. Chronic Myeloid Leukaemia (CML)
    • 2.5.5. Chronic Myelomonocytic Leukaemia
    • 2.5.6. Leukaemia in Children
    • 2.5.7. Survival
  • 2.6. Lymphoma
    • 2.6.1. Non-Hodgkin lymphomas
    • 2.6.2. Hodgkin disease
    • 2.6.3. Survival
  • 2.7. Myeloma
    • 2.7.1. Survival

3. The Global Blood Cancer Market by Type of Therapy: Market Forecast to 2028

  • 3.1. An Introduction to Various Types of Therapies
  • 3.2. Chemotherapy
    • 3.2.1. Global Chemotherapy Market Forecast to 2028
    • 3.3.1. Global Targeted Therapy Market Forecast to 2028
  • 3.4. Immunotherapy
    • 3.4.1. Global Immunotherapy Market Forecast to 2028

4. Global Blood Cancer Market by Region: Market Forecast to 2028

  • 4.1. An Introduction to the Market Geography
  • 4.2. United States Blood Cancer Market Forecast to 2028
    • 4.2.1. United States Blood Cancer Market by Disease Type
    • 4.2.2. United States Blood Cancer Market by Type of Therapy: Forecast to 2028
  • 4.3. EU5. Blood Cancer Market Forecast to 2028
    • 4.3.1. EU5. Blood Cancer Market by Disease Type
    • 4.3.2. EU5. Blood Cancer Market Forecast by Type of Therapy: Forecast to 2028
    • 4.3.3. EU5. Blood Cancer Market by Country Share, 2018 and 2028
  • 4.4. BRIC Blood Cancer Market Forecast to 2028
    • 4.4.1. BRIC Blood Cancer Market by Disease Type
    • 4.4.2. BRIC Blood Cancer Market by Type of Therapy: Forecast to 2028
    • 4.4.3. BRIC Countries Blood Cancer Market
      • 4.4.3.1. Brazil
      • 4.4.3.2. India
      • 4.4.3.3. Russia
      • 4.4.3.4. China
  • 4.4. Japan Blood Cancer Market Forecast to 2028
    • 4.4.1. Japan Blood Cancer Market: by Disease Type
    • 4.4.2. Japan Blood Cancer Market by Type of Therapy: Forecast to 2028

5. Leading Companies in the Blood Cancer Market

  • 5.1. Introduction
    • 5.1.1. Amgen Inc.
      • 5.1.1.1. Business Overview
      • 5.1.1.2. Recent Financials
      • 5.1.1.3. Product Offerings
      • 5.1.1.4. Recent developments
    • 5.1.2. AstraZeneca PLC
      • 5.1.2.1. Business Overview
      • 5.1.2.2. Recent Financials
      • 5.1.2.3. Product Offerings
      • 5.1.2.4. Recent developments
    • 5.1.3. Bayer AG
      • 5.1.3.1. Business Overview
      • 5.1.3.2. Recent Financials
      • 5.1.3.3. Product Offerings
      • 5.1.3.4. Recent developments
    • 5.1.4. Bristol-Myers Squibb Company
      • 5.1.4.1. Business Overview
      • 5.1.4.2. Recent Financials
      • 5.1.4.3. Product Offerings
      • 5.1.4.4. Recent developments
    • 5.1.5. Celgene Corporation
      • 5.1.5.1. Business Overview
      • 5.1.5.2. Recent Financials
      • 5.1.5.3. Product Offerings
      • 5.1.5.4. Recent developments
    • 5.1.6. Roche
      • 5.1.6.1. Business Overview
      • 5.1.6.2. Recent Financials
      • 5.1.6.3. Product Offerings
      • 5.1.6.4. Recent developments
    • 5.1.7. Johnson & Johnson
      • 5.1.7.1. Business Overview
      • 5.1.7.2. Recent Financials
    • 5.1.8. Novartis
      • 5.1.8.1. Business Overview
      • 5.1.8.2. Recent Financials
      • 5.1.8.3. Product Offerings
      • 5.1.8.4. Recent developments
    • 5.1.9. Pfizer Inc.
      • 5.1.9.1. Business Overview
      • 5.1.9.2. Recent Financials
      • 5.1.9.3. Product Offerings
      • 5.1.9.4. Recent Developments

6. Blood Cancer: R&D Pipeline

  • 6.1. Blood Cancer: R&D Pipeline
    • 6.1.1. Drugs for Leukemia
    • 6.1.2. Drugs for Lymphoma
    • 6.1.3. Multiple Myeloma
    • 6.1.4. Other Major Drugs Under Different Stages of Development

7. Qualitative Analysis

  • 7.1. Porter's Five Forces Analysis
    • 7.1.1. Bargaining power of buyers (MEDIUM)
    • 7.1.2. Bargaining power of suppliers (LOW)
    • 7.1.3. Industry rivalry (HIGH)
    • 7.1.4. Threat of new entrants
    • 7.1.5. Threat of substitutes (HIGH)
  • 7.2. Market Dynamics of Blood Cancer Market
    • 7.2.1. Trends
    • 7.2.2. Drivers
    • 7.2.3. Challenges

8. Conclusions & Recommendations

  • 8.1. Key Takeaway
  • 8.2. Conclusion

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top